Zentalis Pharmaceuticals Inc expected to post a loss of 91 cents a share - Earnings Preview

Zentalis Pharmaceuticals

03/11/2023 17:48

* Zentalis Pharmaceuticals Inc  ZNTL.OQ   ZNTL.O  is
expected
to show no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Zentalis
Pharmaceuticals
Inc is for a loss of 91 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 11 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zentalis
Pharmaceuticals Inc is $50​, above​ its last closing price
of $16.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.02       -1.04      -1.85     Missed  -78.3
 Mar. 31 2023  -0.98       -1.02      -1.07     Missed  -5
 Dec. 31 2022  -1.01       -1.06      -0.92     Beat    13.2​
 Sep. 30 2022  -1.15       -1.17      -0.96     Beat    17.9
 ​​Jun.        -1.18       -1.19      -1.34     Missed  -13
 30 2022                                                
 Mar. 31 2022  -1.21       -1.21      -1.31     Missed  -7.8​
 Dec. 31 2021  -1.45       -1.49      -1.11     Beat    25.8
 Sep. 30 2021  -1.31       -1.31      -1.25     Beat    4.6
 This summary was machine generated November 3 at 17:48 GMT.  All
figures in US dollars  unless otherwise stated